AI models have been shown capable of predicting local and distant tumor recurrence in glioma patients from baseline MRI data. While the high odds ratios reported from the multicenter study are encouraging, the evidence comes mainly from small, single-center, retrospective cohorts, so larger prospective multicenter studies are needed before clinical adoption.